NVTA News

AltheaDx, which offers personalized genetic diagnostic tests to predict adverse drug reactions, withdrew its plans for an initial public offering on Monday. AltheaDx had originally filed to raise $60 million (4.6 million shares at $12-$14) in mid-February and was being pitched at a fully diluted market cap of $168 million and an enterprise value of $120 million. ...read more

RainDance Technologies, which sells systems that perform non-invasive genetic analysis, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Genetic testing companies have been active in the IPO market this year. Invitae (NVTA) has gained 19% after it priced above the range in February. Autogenomics (AGMX) and AltheaDx (IDGX) planned to...read more

There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: • 10 IPOs priced in February, down from 20 in 2014 • These returned 7.5% on average; ...read more

Five companies had below-average returns and brought the number 2015 IPOs up to 22, a 39% decline from this time last year... IPO highlights during the week of February 9, 2015 • ...read more